Triple Negative Breast Neoplasms
Information
- Disease name
- Triple Negative Breast Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03818685 | Active, not recruiting | Phase 2 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | July 2, 2019 | May 1, 2024 |
| NCT03997123 | Active, not recruiting | Phase 3 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | June 25, 2019 | March 18, 2024 |
| NCT02926196 | Active, not recruiting | Phase 3 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab | June 17, 2016 | October 2025 |
| NCT03036488 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | March 7, 2017 | September 30, 2025 |
| NCT04504669 | Active, not recruiting | Phase 1 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | August 18, 2020 | January 31, 2025 |
| NCT03225547 | Active, not recruiting | Phase 2 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | February 12, 2018 | September 2025 |
| NCT03310957 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | February 27, 2018 | December 31, 2024 |
| NCT03371017 | Active, not recruiting | Phase 3 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | January 11, 2018 | June 30, 2024 |
| NCT03396445 | Active, not recruiting | Phase 1 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | February 18, 2018 | October 25, 2024 |
| NCT04251533 | Active, not recruiting | Phase 3 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | June 8, 2020 | September 2, 2024 |
| NCT04191135 | Active, not recruiting | Phase 2 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | December 19, 2019 | November 18, 2025 |
| NCT01969643 | Completed | Phase 1 | A Safety Study of SGN-LIV1A in Breast Cancer Patients | October 22, 2013 | February 4, 2023 |
| NCT03539965 | Completed | Triple-negative Breast Cancer: a New Perspective on Biomarkers | January 1, 2010 | December 31, 2014 | |
| NCT03092934 | Completed | Phase 1/Phase 2 | A Study of AK-01 (LY3295668) in Solid Tumors | May 29, 2017 | April 20, 2020 |
| NCT02622074 | Completed | Phase 1 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | January 27, 2016 | November 18, 2019 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT04879849 | Completed | Phase 1 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | September 9, 2021 | April 30, 2024 |
| NCT02789332 | Completed | Phase 2 | Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency | September 2016 | February 2020 |
| NCT02348320 | Completed | Phase 1 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | June 17, 2015 | March 12, 2020 |
| NCT06380816 | Not yet recruiting | Phase 1/Phase 2 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | May 2024 | November 2029 |
| NCT05067530 | Not yet recruiting | Phase 2 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study | January 1, 2022 | December 6, 2026 |
| NCT06154109 | Not yet recruiting | Phase 2 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | November 25, 2023 | March 30, 2026 |
| NCT05973864 | Not yet recruiting | Phase 3 | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | September 2024 | January 2029 |
| NCT06400472 | Recruiting | Phase 1 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | May 6, 2024 | April 2027 |
| NCT03742102 | Recruiting | Phase 1/Phase 2 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | December 21, 2018 | November 14, 2024 |
| NCT05194072 | Recruiting | Phase 1 | A Study of SGN-B7H4V in Advanced Solid Tumors | January 12, 2022 | January 31, 2027 |
| NCT05208762 | Recruiting | Phase 1 | A Study of SGN-PDL1V in Advanced Solid Tumors | October 25, 2022 | December 31, 2026 |
| NCT05252390 | Recruiting | Phase 1/Phase 2 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | March 29, 2022 | November 2026 |
| NCT05435352 | Recruiting | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment | June 6, 2022 | December 31, 2025 | |
| NCT05485766 | Recruiting | Phase 2 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | February 29, 2024 | September 30, 2027 |
| NCT05544929 | Recruiting | Phase 1 | A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | October 26, 2022 | February 20, 2026 |
| NCT06067061 | Recruiting | Phase 1/Phase 2 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | April 5, 2024 | April 5, 2031 |
| NCT06157892 | Recruiting | Phase 1/Phase 2 | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | May 20, 2024 | January 31, 2030 |
| NCT06246968 | Recruiting | Phase 1 | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | January 29, 2024 | January 29, 2027 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT06365788 | Recruiting | Phase 2 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer | April 8, 2024 | December 2027 |
| NCT06385990 | Recruiting | Phase 2 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | March 29, 2024 | March 29, 2027 |
| NCT04335669 | Recruiting | Phase 3 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | December 20, 2019 | June 30, 2035 |
| NCT04561362 | Recruiting | Phase 1/Phase 2 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | July 17, 2020 | December 2025 |
| NCT04895709 | Recruiting | Phase 1/Phase 2 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | May 27, 2021 | September 15, 2026 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05020860 | Recruiting | Phase 2 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | April 18, 2023 | November 2029 |
| NCT02124902 | Terminated | Phase 2 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity | July 7, 2014 | December 31, 2021 |
| NCT02299635 | Terminated | Phase 2 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | February 3, 2015 | January 14, 2016 |
| NCT02720185 | Terminated | Phase 2 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | May 3, 2017 | February 8, 2022 |
| NCT04489940 | Terminated | Phase 2 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | October 12, 2020 | July 8, 2022 |
| NCT03199040 | Terminated | Phase 1 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | July 23, 2019 | May 1, 2023 |
| NCT03838367 | Unknown status | Phase 1/Phase 2 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | April 22, 2019 | September 16, 2022 |
| NCT03692689 | Unknown status | Phase 2 | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | July 20, 2018 | December 31, 2019 |
| NCT04669522 | Unknown status | Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer | December 2020 | December 2021 | |
| NCT06057636 | Withdrawn | N/A | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | September 8, 2023 | May 8, 2024 |
| NCT02539017 | Withdrawn | Phase 2 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | November 2015 | |
| NCT02427581 | Withdrawn | Phase 1 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | September 29, 2015 | December 31, 2025 |
| NCT02685306 | Withdrawn | Phase 2 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | March 2016 | September 2017 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D064726